Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global depression drugs market size reached US$ 17.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 21.4 Billion by 2027, exhibiting a growth rate (CAGR) of 3.62% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Apart from this, with the surge in the cases of the coronavirus disease (COVID-19), there is a considerable degree of fear, worry and concern in the population. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group’s latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on drug class, disorder type, drug type, and distribution channel.

Breakup by Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others
     

Breakup by Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others
     

Breakup by Drug Type:

  • Generic Drugs
  • Branded Drugs
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
     

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
     

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Drug Class, Disorder Type, Drug Type, Distribution Channel., Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd and Sebela Pharmaceuticals
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction

    4.1    Overview
    4.2    Key Industry Trends
5   Global Depression Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Breakup by Drug Class
    5.5    Market Breakup by Disorder Type
    5.6    Market Breakup by Drug Type
    5.7    Market Breakup by Distribution Channel
    5.8    Market Breakup by Region
    5.9    Market Forecast
6   Market Breakup by Drug Class
    6.1    Atypical Antipsychotics 
        6.1.1    Market Trends
        6.1.2    Market Forecast
    6.2    Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
        6.2.1    Market Trends
        6.2.2    Market Forecast
    6.3    Selective Serotonin Reuptake Inhibitors (SSRIs)
        6.3.1    Market Trends
        6.3.2    Market Forecast
    6.4    Central Nervous System (CNS) Stimulants
        6.4.1    Market Trends
        6.4.2    Market Forecast
    6.5    Tricyclic Antidepressants
        6.5.1    Market Trends
        6.5.2    Market Forecast
    6.6    Monoamine Oxidase Inhibitors
        6.6.1    Market Trends
        6.6.2    Market Forecast
    6.7    Others
        6.7.1    Market Trends
        6.7.2    Market Forecast
7   Market Breakup by Disorder Type
    7.1    Major Depressive Disorder
        7.1.1    Market Trends
        7.1.2    Market Forecast
    7.2    Obsessive-Compulsive Disorder
        7.2.1    Market Trends
        7.2.2    Market Forecast
    7.3    Generalized Anxiety Disorder
        7.3.1    Market Trends
        7.3.2    Market Forecast
    7.4    Panic Disorder 
        7.4.1    Market Trends
        7.4.2    Market Forecast
    7.5    Others 
        7.5.1    Market Trends
        7.5.2    Market Forecast
8   Market Breakup by Drug Type
    8.1    Generic Drugs
        8.1.1    Market Trends
        8.1.2    Market Forecast
    8.2    Branded Drugs
        8.2.1    Market Trends
        8.2.2    Market Forecast
9   Market Breakup by Distribution Channel
    9.1    Hospital Pharmacies
        9.1.1    Market Trends
        9.1.2    Market Forecast
    9.2    Retail Pharmacies
        9.2.1    Market Trends
        9.2.2    Market Forecast
    9.3    Online Pharmacies
        9.3.1    Market Trends
        9.3.2    Market Forecast
    9.4    Others
        9.4.1    Market Trends
        9.4.2    Market Forecast
10  Market Breakup by Region
    10.1    North America
        10.1.1    Market Trends
        10.1.2    Market Forecast
    10.2    Europe
        10.2.1    Market Trends
        10.2.2    Market Forecast
    10.3    Asia Pacific
        10.3.1    Market Trends
        10.3.2    Market Forecast
    10.4    Middle East and Africa
        10.4.1    Market Trends
        10.4.2    Market Forecast
    10.5    Latin America
        10.5.1    Market Trends
        10.5.2    Market Forecast
11  SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12  Value Chain Analysis
13  Porter’s Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14  Price Analysis
15  Competitive Landscape

    15.1    Market Structure
    15.2    Key Players
    15.3    Profiles of Key Players
        15.3.1    Otsuka Pharmaceutical
        15.3.2    Pfizer
        15.3.3    Eli Lilly and Company
        15.3.4    AstraZeneca
        15.3.5    Novartis
        15.3.6    Bristol-Myers Squibb
        15.3.7    GlaxoSmithKline
        15.3.8    Takeda Pharmaceutical Company
        15.3.9    Allergan
        15.3.10   Johnson & Johnson
        15.3.11   Zhejiang NHU Company Ltd
        15.3.12   Sebela Pharmaceuticals

List of Figures

Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2021
Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2021
Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2021
Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2021
Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 9: Global: Depression Drugs Industry: SWOT Analysis
Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
Figure 11: Global: Depression Drugs Industry: Porter’s Five Forces Analysis
Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2016 & 2021
Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2022-2027
Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2016 & 2021
Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2022-2027
Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2016 & 2021
Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2022-2027
Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2016 & 2021
Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2022-2027
Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2022-2027

List of Tables

Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2022-2027
Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2022-2027
Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Depression Drugs Market Structure
Table 8: Global: Depression Drugs Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global depression drugs market was valued at US$ 17.2 Billion in 2021.

Sudden outbreak of the COVID-19 pandemic has negatively impacted the mental health of individuals due to the imposition of lockdown regulations, loss of employments, increased health risks, etc., which are augmenting the demand for depression drugs.

We expect the global depression drugs market to exhibit a CAGR of 3.62% during 2022-2027.

The increasing prevalence of social anxiety and depression due to rising work pressure and busy schedules, represents one of the key factors driving the global depression drugs market.

Based on the disorder type, the global depression drugs market has been bifurcated into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. Among these, major depressive disorder holds the majority of the total market share.

Based on the distribution channel, the global depression drugs market can be segmented into retail pharmacies, hospital pharmacies, online pharmacies, and other pharmacies. Currently, retail pharmacies exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.

Some of the major players in the global depression drugs market include Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links